

ForPatients

by Roche

Chronic Hepatitis B Hepatitis B Virus

A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

Trial Status
Completed

Trial Runs In
14 Countries

Trial Identifier
NCT04225715 2019-002086-35
WV41073

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a study designed to evaluate the safety, tolerability and efficacy of New Molecular Entity (NME) combination therapies in Chronic Hepatitis B (CHB) participants with preserved liver function and without significant fibrosis/cirrhosis. The platform design allows comparison of multiple NME combination therapies against a common control, and introduction of additional treatment arms at later study time points. Each arm will consist of a screening phase (up to 8 weeks), treatment phase (up to 48 weeks) and post-treatment follow-up phase (48 weeks). The safety and efficacy will be monitored throughout the study.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT04225715 2019-002086-35 WV41073
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 65 Years

Healthy Volunteers
No
